Literature DB >> 8985284

The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis.

P C Adams1, Y Deugnier, R Moirand, P Brissot.   

Abstract

The aim of this study was to investigate the relationship between iron overload, age, and clinical symptoms in genetic hemochromatosis. The relationship was studied between clinical symptoms and liver iron concentration, serum ferritin, and iron removed in a retrospective study of 410 homozygotes diagnosed using strict criteria. No significant relationship was found between liver iron concentration, iron removed by venesection, and serum ferritin level with age. The prevalence of cirrhosis, diabetes, cardiac disease, pigmentation, and fatigue increased as liver iron concentration increased. The most common presentations at diagnosis were fatigue or as an incidental finding in all age groups. Twenty-seven percent of patients (110 of 410) had no clinical symptoms of hemochromatosis. Iron accumulation is highly variable in patients with genetic hemochromatosis. The significant relationship between liver iron concentration and cirrhosis, diabetes, cardiac disease, pigmentation, and fatigue confirms the importance of iron toxicity in the pathogenesis of hepatic and extrahepatic disease. The nonspecific nature of the presenting features in patients and the presence of significant clinical symptoms in patients discovered through family investigations underscore the importance of family and population screening for hemochromatosis.

Entities:  

Mesh:

Year:  1997        PMID: 8985284     DOI: 10.1002/hep.510250130

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

Review 1.  Magnetic resonance imaging quantification of liver iron.

Authors:  Claude B Sirlin; Scott B Reeder
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

2.  Different forms of iron accumulation in the liver on MRI.

Authors:  İlkay S İdilman; Deniz Akata; Mustafa Nasuh Özmen; Muşturay Karçaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

3.  IL1RN genotype as a risk factor for joint pain in hereditary haemochromatosis?

Authors:  E J Walker; J Riddell; H J Rodgers; M L Bassett; S R Wilson; J A Cavanaugh
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

4.  ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.

Authors:  Zhi Liu; Jing Qiao; Tamas Nagy; May P Xiong
Journal:  J Control Release       Date:  2018-05-22       Impact factor: 9.776

5.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

6.  Targeted screening for genetic haemochromatosis: a combined phenotype/genotype approach.

Authors:  M Bhavnani; D Lloyd; J Marples; K Pendry; M Worwood
Journal:  J Clin Pathol       Date:  2006-05       Impact factor: 3.411

Review 7.  Gender specific medicine in liver diseases: a point of view.

Authors:  Marilena Durazzo; Paola Belci; Alessandro Collo; Vanessa Prandi; Erika Pistone; Maria Martorana; Roberto Gambino; Simona Bo
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

8.  Hemochromatosis: a model of metal-related human toxicosis.

Authors:  Pierre Brissot; Thibault Cavey; Martine Ropert; François Gaboriau; Olivier Loréal
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-15       Impact factor: 4.223

Review 9.  Hereditary hemochromatosis: a neglected diagnosis in orthopedics: a series of 7 patients with ankle arthritis, and a review of the literature.

Authors:  Ake Carlsson
Journal:  Acta Orthop       Date:  2009-06       Impact factor: 3.717

10.  The H63D variant in the HFE gene predisposes to arthralgia, chondrocalcinosis and osteoarthritis.

Authors:  B Z Alizadeh; O T Njajou; J M W Hazes; A Hofman; P E Slagboom; H A P Pols; C M van Duijn
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.